enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 71.8% in September

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 13,400 shares, a growth of 71.8% from the September 15th total of 7,800 shares. Based on an average trading volume of 3,900 shares, the days-to-cover ratio is currently 3.4 days.

enGene Stock Up 2.3 %

ENGNW traded up $0.03 on Monday, hitting $1.33. The company had a trading volume of 10,666 shares, compared to its average volume of 20,842. enGene has a 1-year low of $0.39 and a 1-year high of $6.50. The company’s fifty day moving average price is $1.28 and its 200 day moving average price is $2.23.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.